SGP
What one share of SpyGlass Pharma holds
Surgical and Medical Instruments and Apparatus
We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
SpyGlass Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.88 |
|---|---|
| Capex (buildings and equipment) | $0.22 |
| Free cash flow | −$3.44 |
| Cash and investments | $6.67 |
| Book value | $6.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$16.31 | $1.11 | −$13.43 | — | −$27.53 |
| 2025 | — | −$17.98 | $0.36 | −$15.11 | — | −$44.85 |